Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
PRNewswire - December 2, 2003
"World AIDS Day is the ideal time for everyone to commit to being tested," said Johnson. "It's a day when we can take on the rampant spread of HIV one person at a time," he added. Calypte's Chairman Anthony Cataldo stated, "Early detection can significantly alter the quality of life, and can help prevent the spread of HIV and can ultimately save lives."
Magic Johnson first appeared on NBC's Today Show followed by an interview on BET and ABC radio. Both Mr. Cataldo and Mr. Johnson appeared on MSNBC and Fox News, Your World with Neal Cavuto to discuss the company and highlight the need for HIV/AIDS testing.
To access these events please go to the company's web site at http://www.calypte.com
About The Magic Johnson Foundation
The Magic Johnson Foundation was established in 1991 as a single-disease organization that worked to raise funds for community-based organizations dealing with HIV/AIDS education and prevention programs. The Foundation has since responded to the growing need to address all aspects of our youth's lives by expanding its mission. This expanded mission emphasizes the Foundation's focus on supporting community-based organizations and developing programs that serve the health, educational and social needs of those residing in inner-city communities. In addition, the Foundation has made a strong commitment to raise awareness about many of the health and social concerns that threaten under-served communities.
About Calypte Biomedical
Calypte Biomedical Corporation, headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA-approved serum HIV-1 antibody Western Blot test. The Company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand.
The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.
Investor Relations Contact:
Tim Clemensen - 212-843-9337
email: tclemensen@rubensteinir.com
SOURCE Calypte Biomedical Corporation
Web Site: http://www.calypte.com
031202
PR031209
Copyright © 2003 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .